Vericiguat: A Novel Soluble Guanylate Cyclase Stimulator For Use in Patients with Heart Failure.

Publication/Presentation Date



Heart failure affects 6.2 million Americans and is increasing annually in its frequency. Treatment of heart failure has been at the forefront of medical advancements due to the financial burden on our health care system. As such, changes to the guidelines regarding standard of care has been evolving over the last decade with the recent additions of sacubitril-valsartan and SGLT2 inhibitors to standard of care in the treatment of heart failure. Despite the aforementioned expansions in treatment options, heart failure continues to have a significant impact on the American healthcare system. Most recently, a novel drug, Vericiguat that targets an unprecedented pathway for the treatment of heart failure, was FDA approved for the management of patients with heart failure with a reduced ejection fraction with a recent hospitalization or need for outpatient IV diuretics. In clinical trials, Vericiguat was associated with a reduction in death from cardiovascular causes and first hospitalization in comparison to placebo. The aim of this review is to provide a comprehensive literature analysis of the various trials surrounding the approval of Vericiguat, and to both inform and synthesize the data surrounding the clinical use of Vericiguat. The introduction of Vericiguat should be considered as a treatment option in patients to decrease the mortality/morbidity of heart failure with reduced ejection fraction, and to increase the quality of life.




Medicine and Health Sciences




Department of Medicine, Cardiology Division, Department of Medicine Fellows and Residents, USF-LVHN SELECT Program, USF-LVHN SELECT Program Students

Document Type